Logo image of EKSO

EKSO BIONICS HOLDINGS INC (EKSO) Stock Fundamental Analysis

NASDAQ:EKSO - Nasdaq - US2826443010 - Common Stock - Currency: USD

0.442  +0.01 (+2.79%)

Premarket: 0.4499 +0.01 (+1.79%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to EKSO. EKSO was compared to 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of EKSO have multiple concerns. EKSO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EKSO had negative earnings in the past year.
EKSO had a negative operating cash flow in the past year.
In the past 5 years EKSO always reported negative net income.
EKSO had a negative operating cash flow in each of the past 5 years.
EKSO Yearly Net Income VS EBIT VS OCF VS FCFEKSO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

EKSO has a worse Return On Assets (-42.51%) than 62.96% of its industry peers.
EKSO has a worse Return On Equity (-89.16%) than 62.43% of its industry peers.
Industry RankSector Rank
ROA -42.51%
ROE -89.16%
ROIC N/A
ROA(3y)-43.98%
ROA(5y)-46.15%
ROE(3y)-89.67%
ROE(5y)-131.07%
ROIC(3y)N/A
ROIC(5y)N/A
EKSO Yearly ROA, ROE, ROICEKSO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

EKSO's Gross Margin of 53.06% is in line compared to the rest of the industry. EKSO outperforms 46.03% of its industry peers.
EKSO's Gross Margin has improved in the last couple of years.
EKSO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.01%
GM growth 5Y1.79%
EKSO Yearly Profit, Operating, Gross MarginsEKSO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

EKSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
EKSO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, EKSO has more shares outstanding
EKSO has a better debt/assets ratio than last year.
EKSO Yearly Shares OutstandingEKSO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
EKSO Yearly Total Debt VS Total AssetsEKSO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -12.73, we must say that EKSO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -12.73, EKSO is not doing good in the industry: 83.60% of the companies in the same industry are doing better.
EKSO has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
EKSO has a Debt to Equity ratio (0.30) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Altman-Z -12.73
ROIC/WACCN/A
WACC8.04%
EKSO Yearly LT Debt VS Equity VS FCFEKSO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 2.50 indicates that EKSO has no problem at all paying its short term obligations.
With a Current ratio value of 2.50, EKSO perfoms like the industry average, outperforming 46.03% of the companies in the same industry.
A Quick Ratio of 1.89 indicates that EKSO should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.89, EKSO is in line with its industry, outperforming 47.09% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.5
Quick Ratio 1.89
EKSO Yearly Current Assets VS Current LiabilitesEKSO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

EKSO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.18%, which is quite impressive.
The Revenue has decreased by -1.93% in the past year.
The Revenue has been growing slightly by 5.19% on average over the past years.
EPS 1Y (TTM)48.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)-1.93%
Revenue growth 3Y16.8%
Revenue growth 5Y5.19%
Sales Q2Q%5.01%

3.2 Future

The Earnings Per Share is expected to grow by 30.35% on average over the next years. This is a very strong growth
EKSO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.16% yearly.
EPS Next Y42.74%
EPS Next 2Y34.95%
EPS Next 3Y30.35%
EPS Next 5YN/A
Revenue Next Year23.09%
Revenue Next 2Y29.87%
Revenue Next 3Y30.16%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EKSO Yearly Revenue VS EstimatesEKSO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
EKSO Yearly EPS VS EstimatesEKSO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EKSO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EKSO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EKSO Price Earnings VS Forward Price EarningsEKSO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EKSO Per share dataEKSO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

EKSO's earnings are expected to grow with 30.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.95%
EPS Next 3Y30.35%

More info and screens

0

5. Dividend

5.1 Amount

EKSO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EKSO BIONICS HOLDINGS INC

NASDAQ:EKSO (4/25/2025, 8:03:15 PM)

Premarket: 0.4499 +0.01 (+1.79%)

0.442

+0.01 (+2.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-24 2025-04-24/amc
Earnings (Next)07-28 2025-07-28/amc
Inst Owners19.35%
Inst Owner Change1.3%
Ins Owners6.89%
Ins Owner Change0%
Market Cap12.46M
Analysts82.5
Price Target5.1 (1053.85%)
Short Float %2.42%
Short Ratio3.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-32.47%
Min EPS beat(2)-71.57%
Max EPS beat(2)6.63%
EPS beat(4)2
Avg EPS beat(4)-21.38%
Min EPS beat(4)-71.57%
Max EPS beat(4)6.63%
EPS beat(8)3
Avg EPS beat(8)-21.3%
EPS beat(12)5
Avg EPS beat(12)-16.02%
EPS beat(16)8
Avg EPS beat(16)-9.66%
Revenue beat(2)0
Avg Revenue beat(2)-14.16%
Min Revenue beat(2)-27.08%
Max Revenue beat(2)-1.24%
Revenue beat(4)0
Avg Revenue beat(4)-15.18%
Min Revenue beat(4)-27.08%
Max Revenue beat(4)-1.24%
Revenue beat(8)3
Avg Revenue beat(8)-1.31%
Revenue beat(12)3
Avg Revenue beat(12)-4.57%
Revenue beat(16)6
Avg Revenue beat(16)-1.9%
PT rev (1m)-9.09%
PT rev (3m)-9.09%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-46.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-68.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.7
P/FCF N/A
P/OCF N/A
P/B 0.98
P/tB 1.62
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0.64
BVpS0.45
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.51%
ROE -89.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.06%
FCFM N/A
ROA(3y)-43.98%
ROA(5y)-46.15%
ROE(3y)-89.67%
ROE(5y)-131.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.01%
GM growth 5Y1.79%
F-Score6
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.3%
Cap/Sales 0.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.5
Quick Ratio 1.89
Altman-Z -12.73
F-Score6
WACC8.04%
ROIC/WACCN/A
Cap/Depr(3y)10.97%
Cap/Depr(5y)8.72%
Cap/Sales(3y)0.85%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
EPS Next Y42.74%
EPS Next 2Y34.95%
EPS Next 3Y30.35%
EPS Next 5YN/A
Revenue 1Y (TTM)-1.93%
Revenue growth 3Y16.8%
Revenue growth 5Y5.19%
Sales Q2Q%5.01%
Revenue Next Year23.09%
Revenue Next 2Y29.87%
Revenue Next 3Y30.16%
Revenue Next 5YN/A
EBIT growth 1Y30.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.32%
OCF growth 3YN/A
OCF growth 5YN/A